Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
Aug 19, 2026, 19:09Gregory Lip: PFO Closure in Younger Patients With Cryptogenic Stroke
-
Aug 19, 2026, 18:51Filippo Crea: AF and Alzheimer’s Disease – Does the Anticoagulant Choice Matter for the Brain?
-
Aug 19, 2026, 18:42Alan Nurden: How Procoagulant Platelets Relate to Microparticle Release?
-
Aug 19, 2026, 18:25Ivan Centeno Sáenz: FeNO and Biomass Smoke-Associated Chronic Obstructive Pulmonary Disease
-
Aug 19, 2026, 18:10Ahmad Hazri Mohamed Aris: Strengthening Hemophilia Care and Access to Treatment in Fiji
-
Aug 19, 2026, 17:58Paulomi Ghosh: Delighted to Deliver a Talk on Hemostasis and Hemorrhage Control
-
Aug 19, 2026, 17:34Ryan O’Keefe: Clopidogrel Non-Responders and the Risk of Stent Thrombosis
-
Aug 19, 2026, 17:10Mavis Agnes Kisakye: Raising Awareness and Supporting Patients With Bleeding Disorders
-
Aug 19, 2026, 17:02Daniel Barsanow: ETHIZIA vs TachoSil for Hemostasis During Open Liver Surgery